MX2023014320A - Anticuerpos y composiciones anti-nkg2a. - Google Patents

Anticuerpos y composiciones anti-nkg2a.

Info

Publication number
MX2023014320A
MX2023014320A MX2023014320A MX2023014320A MX2023014320A MX 2023014320 A MX2023014320 A MX 2023014320A MX 2023014320 A MX2023014320 A MX 2023014320A MX 2023014320 A MX2023014320 A MX 2023014320A MX 2023014320 A MX2023014320 A MX 2023014320A
Authority
MX
Mexico
Prior art keywords
compositions
nkg2a antibodies
nkg2a
antibodies
patient
Prior art date
Application number
MX2023014320A
Other languages
English (en)
Spanish (es)
Inventor
Michael Monrad Grandal
Randi Westh Hansen
Anne Worsaae
Franziska Katharina Uhlenbrock
Nikolaj Dietrich
Original Assignee
Servier Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Servier Lab filed Critical Servier Lab
Publication of MX2023014320A publication Critical patent/MX2023014320A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
MX2023014320A 2021-06-01 2022-05-31 Anticuerpos y composiciones anti-nkg2a. MX2023014320A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163195470P 2021-06-01 2021-06-01
PCT/EP2022/064703 WO2022253805A1 (en) 2021-06-01 2022-05-31 Anti-nkg2a antibodies and compositions

Publications (1)

Publication Number Publication Date
MX2023014320A true MX2023014320A (es) 2023-12-13

Family

ID=82117230

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023014320A MX2023014320A (es) 2021-06-01 2022-05-31 Anticuerpos y composiciones anti-nkg2a.

Country Status (17)

Country Link
US (2) US12012450B2 (cg-RX-API-DMAC7.html)
EP (1) EP4347651A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024520577A (cg-RX-API-DMAC7.html)
KR (1) KR20240016991A (cg-RX-API-DMAC7.html)
CN (1) CN117460748A (cg-RX-API-DMAC7.html)
AR (1) AR126001A1 (cg-RX-API-DMAC7.html)
AU (1) AU2022286617A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023024772A2 (cg-RX-API-DMAC7.html)
CA (1) CA3222040A1 (cg-RX-API-DMAC7.html)
CL (1) CL2023003562A1 (cg-RX-API-DMAC7.html)
CO (1) CO2023015982A2 (cg-RX-API-DMAC7.html)
IL (1) IL308695A (cg-RX-API-DMAC7.html)
MX (1) MX2023014320A (cg-RX-API-DMAC7.html)
PE (1) PE20240372A1 (cg-RX-API-DMAC7.html)
PH (1) PH12023553123A1 (cg-RX-API-DMAC7.html)
TW (1) TW202313683A (cg-RX-API-DMAC7.html)
WO (1) WO2022253805A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4644422A1 (en) * 2022-12-28 2025-11-05 BioRay Pharmaceutical Co., Ltd. Anti-nkg2a antibody and use thereof
CN121358774A (zh) * 2023-06-21 2026-01-16 科望(苏州)生物医药科技有限公司 与nkg2a结合的抗体或抗原结合片段及其用途
CN121941711A (zh) * 2024-02-08 2026-04-28 翰思艾泰生物医药科技(武汉)股份有限公司 Nkg2a/cd94靶向抗体及其用途
CN121108342B (zh) * 2025-09-08 2026-03-03 北京明璨生物科技有限公司 包含抗体和nk细胞的组合物在治疗癌症中的用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002522063A (ja) 1998-08-17 2002-07-23 アブジェニックス インコーポレイテッド 増加した血清半減期を有する改変された分子の生成
ATE537190T1 (de) * 2006-06-02 2011-12-15 Regeneron Pharma Hochaffine antikörper gegen den humanen il-6- rezeptor
MX2010007935A (es) 2008-01-24 2010-08-23 Novo Nordisk As Anticuerpo monoclonal humanizado anti-nkg2a humano.
AU2015316993B2 (en) * 2014-09-16 2021-03-18 Innate Pharma Treatment regimens using anti-NKG2A antibodies
EP3209687A1 (en) * 2014-10-23 2017-08-30 Innate Pharma Treatment of cancers using anti-nkg2a agents
WO2017046774A2 (en) 2015-09-16 2017-03-23 Prothena Biosciences Limited Use of anti-mcam antibodies for treatment or prophylaxis of giant cell arteritis, polymyalgia rheumatica or takayasu's arteritis
CN116693685A (zh) * 2016-04-12 2023-09-05 法国施维雅药厂 抗tim-3抗体及组合物
EP3878869A4 (en) 2018-11-07 2023-04-19 Shanghai Hyamab Biotech Co., Ltd. NKG2A ANTIBODIES, METHOD OF PRODUCTION THEREOF AND USE THEREOF
MX2021005708A (es) * 2018-11-16 2021-09-21 Bristol Myers Squibb Co Anticuerpos anti grupo 2a del receptor inhibidor de células asesinas naturales (anti-nkg2a) y usos de los mismos.

Also Published As

Publication number Publication date
US12012450B2 (en) 2024-06-18
JP2024520577A (ja) 2024-05-24
CA3222040A1 (en) 2022-12-08
PH12023553123A1 (en) 2024-03-04
IL308695A (en) 2024-01-01
CN117460748A (zh) 2024-01-26
US20240294638A1 (en) 2024-09-05
EP4347651A1 (en) 2024-04-10
KR20240016991A (ko) 2024-02-06
CL2023003562A1 (es) 2024-07-12
AR126001A1 (es) 2023-08-30
BR112023024772A2 (pt) 2024-02-15
AU2022286617A1 (en) 2023-12-21
WO2022253805A1 (en) 2022-12-08
TW202313683A (zh) 2023-04-01
US20220389100A1 (en) 2022-12-08
PE20240372A1 (es) 2024-03-05
CO2023015982A2 (es) 2024-01-15

Similar Documents

Publication Publication Date Title
PH12023553123A1 (en) Anti-nkg2a antibodies and compositions
ZA202204437B (en) Anti-pd-l1 antibodies and antibody-drug conjugates
PH12022552710A1 (en) Anti-flt3 antibodies and compositions
PH12019500923A1 (en) Anti-pd-1 antibodies and compositions
MX2022003005A (es) Composiciones y metodos de anticuerpos anti-cd39.
MY207784A (en) Anti-cd73 antibodies
PH12018502112B1 (en) Anti-tim-3 antibodies and compositions
MX2023007840A (es) Anticuerpos anti-properdina monovalentes y fragmentos de anticuerpo.
MX2018003936A (es) Anticuerpos anti proteina de muerte celular programada 1 (pd-1) y composiciones.
MX2024005392A (es) Métodos para tratar cánceres y potenciar la eficacia de anticuerpos biespecíficos para bcmaxcd3.
PH12022551036A1 (en) Anti-mesothelin eribulin antibody-drug conjugates and methods of use
MX2022010306A (es) Epitopos y anticuerpos del homologo del oncogen viral del sarcoma de la rata kirsten (kras).
MX2023004280A (es) Composiciones y metodos para el tratamiento de la enfermedad ocular tiroidea.
MX2023008701A (es) Quinolinas y azaquinolinas como inhibidores de cumulo de diferenciacion 38 (cd38).
NZ754676A (en) Use of anti-sclerostin antibodies in the treatment of osteogenesis imperfecta
MX2022010161A (es) Proteínas biespecíficas anti-her2 diseñadas.
MX2023001143A (es) Anticuerpos anti-cd228 y conjugados de anticuerpos-farmacos.
PH12022551021A1 (en) Sequential anti-cd19 therapy
MX2022015375A (es) Conjugados de farmaco-anticuerpo anti-factor de tejido y su uso en el tratamiento de cancer.
MX2020003219A (es) Anticuerpos que tienen especificidad para btn2 y usos de los mismos.
MX2022005238A (es) Tratamiento del cancer usando un anticuerpo biespecifico contra hla-a2/wt1 x cd3 y lenalidomida.
MX2021011040A (es) Anticuerpos dirigidos contra c5ar.
MY209381A (en) Anti-axl antibodies and compositions
ZA202205813B (en) Trpv1 epitopes and antibodies
MX2022011027A (es) Composiciones y metodos para el tratamiento del cancer.